Jason Johnson, MD, MBA, DABR
Cards
About
Research
Publications
2025
Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel CB, Yang Z, Liu HA, Johnson JM. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. J Comput Assist Tomogr 2025 PMID: 39876523, DOI: 10.1097/RCT.0000000000001716.Peer-Reviewed Original ResearchRadiologist, trainee, and logistical factors impacting the timeliness of CTA head and neck reporting in stroke code activations.
Zaree O, Nguyen J, de Oliveira Santo I, Kertam A, Rahmani S, Johnson J, Tu L. Radiologist, trainee, and logistical factors impacting the timeliness of CTA head and neck reporting in stroke code activations. American Journal Of Neuroradiology 2025, ajnr.a8660. PMID: 39832953, DOI: 10.3174/ajnr.a8660.Peer-Reviewed Original ResearchStroke code activationAttending radiologistsTimeliness of reportingEmergency department settingRadiologist characteristicsCare settingsMultivariate regression modelImprove workflow efficiencyDepartment settingStroke codeModifiable factorsDescriptive statisticsSecondary analysisCoding activitiesReport factorsPatient ageObservational studyWorkflow efficiencyShift typeMedian TATMultivariate regressionInterquartile rangeRegression modelsCTA reportsLogistical factors
2024
The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey
Samir A. Dagher, MD, Ho-Ling Liu, PhD, Burak Berksu Ozkara, MD, Susana Calle, MD, Diana Kaya, MD, Maria K. Gule, MD, Noah N. Chasen, MD, Dawid Schellingerhout, MD, Kim O. Learned, MD, Komal B. Shah, MD, Jason M. Johnson, MD, Jia Sun, PhD, Donald F. Schomer, MD, Vinodh A. Kumar, MD, Max Wintermark, MD, Nazanin K. Majd, MD, PhD, Joo Yeon Nam, MD, Melissa M. Chen, MD. The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey. AJR 2024 Aug 14 [published online]. Accepted manuscript. doi:10.2214/AJR.24.31595Peer-Reviewed Original ResearchDifferential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study.
Figueredo LF, Mejía-Cordovez JA, Gomez-Amarillo DA, Hakim F, Pimienta-Redondo HD, Almeida JP, Kehayov I, Angelova P, Apostolov G, Luzzi S, Baldoncini M, Johnson JM, Ordóñez-Rubiano EG. Differential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study. Clin Neurol Neurosurg 2024, 241: 108305. PMID: 38713964, DOI: 10.1016/j.clineuro.2024.108305.Peer-Reviewed Original ResearchTucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
O'Brien B, Murthy R, Berry D, Singareeka Raghavendra A, Gule-Monroe M, Johnson J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Melisko M, Morikawa A, Ferguson S, de Groot J, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin N, Stringer-Reasor E. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. Journal Of Clinical Oncology 2024, 42: 2018-2018. DOI: 10.1200/jco.2024.42.16_suppl.2018.Peer-Reviewed Original ResearchHER2+ breast cancerLeptomeningeal metastasesPatient-reported outcomesBreast cancerObjective responseClinical examCSF cytologyEvidence of clinically meaningful benefitHER2-targeted tyrosine kinase inhibitorsMedian time to CNS progressionMetastatic HER2+ breast cancerKarnofsky performance status >Treatment of leptomeningeal metastasesAbnormal CSF cytologyPerformance status >Targeted neurological deficitsMDASI-BTPhase 2 studyTyrosine kinase inhibitorsClinically meaningful benefitPre-specified timepointsPreliminary efficacy dataCNS progressionMedian OSCNS metastasesAdditive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas
Yadav D, Upadhyay R, Kumar V, Chen M, Johnson J, Langshaw H, Curl B, Farhat M, Talpur W, Beckham T, Yeboa D, Swanson T, Ghia A, Li J, Chung C. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas. Practical Radiation Oncology 2024, 14: e449-e457. PMID: 38685448, DOI: 10.1016/j.prro.2024.04.009.Peer-Reviewed Original ResearchPseudo-progressionResponse assessmentInterobserver agreementImprove response assessmentPost-operative MRIFollow-up MRIFollow-up imagingEvaluate treatment responseHigh-grade gliomasIndependent blinded reviewIdentification of patientsClinical trial enrollmentWeeks of RTPartial response(PRStable disease(SDRT planningSalvage treatmentTumor responseEarly time pointsMedian intervalImprove patient outcomesTrue progressionProspective studyTreatment responseTumor progressionExpert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation.
Hoebel KV, Bridge CP, Ahmed S, Akintola O, Chung C, Huang RY, Johnson JM, Kim A, Ly KI, Chang K, Patel J, Pinho M, Batchelor TT, Rosen BR, Gerstner ER, Kalpathy-Cramer J. Expert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation. Radiol Artif Intell 2024, 6: e220231. PMID: 38197800, DOI: 10.1148/ryai.220231.Peer-Reviewed Original Research
2023
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Nagarajan P, Maronge J, Johnson J, Rosenthal D, Myers J, Gross N. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology - Head & Neck Surgery 2023, 149: 847-849. PMID: 37535378, PMCID: PMC10401391, DOI: 10.1001/jamaoto.2023.1729.Peer-Reviewed Original ResearchAdvances in the Radiological Evaluation of and Theranostics for Glioblastoma
Hooper G, Ansari S, Johnson J, Ginat D. Advances in the Radiological Evaluation of and Theranostics for Glioblastoma. Cancers 2023, 15: 4162. PMID: 37627190, PMCID: PMC10453051, DOI: 10.3390/cancers15164162.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPrognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience
Matsui J, Allen P, Perlow H, Johnson J, Paulino A, McAleer M, Fouladi M, Grosshans D, Ghia A, Li J, Zaky W, Chintagumpala M, Palmer J, McGovern S. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. Journal Of Neuro-Oncology 2023, 163: 717-726. PMID: 37440097, DOI: 10.1007/s11060-023-04386-4.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Neuroradiology
Get In Touch
Contacts
Appointment Number